This article was originally published in The Gray Sheet
Firm's board of directors approves the repurchase of up to 200,000 shares of common "as a result of what the company views as the depressed market price of its common stock," the electromedical treatment devices manufacturer announces. The board also extends to Feb. 28, 1995 the expiration date of the firm's currently outstanding warrants issued in June 1991 and expiring June 19, 1994. Two warrants can be used to buy one share of Staodyn common stock at $5 per share; 920,000 of these warrants are outstanding. The firm notes it has begun shipping its Dermapulse wound management system to Canada and expects to begin marketing the electrostimulation device in Europe within six months
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.